DÄ internationalArchiveReferences
References

Review article

Disease Management Programs for Type 2 Diabetes in Germany

Dtsch Arztebl Int 2014; 111(26): 453-63. DOI: 10.3238/arztebl.2014.0453

Fuchs, S; Henschke, C; Blümel, M; Busse, R

1. Busse R, Blümel M, Scheller-Kreinsen D, Zentner A: Tackling chronic disease in Europe: Strategies, interventions and challenges. Observatory Studies Series No. 20. Copenhagen: World Health Organization on behalf of the European Observatory on Health Systems and Policies 2010.
2.American Diabetes Association: Position Statement. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2012; 35: 64–71. CrossRef MEDLINE PubMed Central
3.Danaei G, Finucane MM, Lu Y, et al.: National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 2011; 378: 31–40. CrossRef MEDLINE
4.Heidmann C, Du Y, Schubert I, Rathmann W, Scheidt-Nave C: Prevalence and temporal trend of known diabetes mellitus. Results of the German Health Interview and Examination Survey for Adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56: 668–77. MEDLINE
5.Koster I, Schubert I, Huppertz E: Follow up of the CoDiM-Study: cost of diabetes mellitus 2000–2009. Dtsch Med Wochenschr 2012; 137: 1013–6. CrossRef MEDLINE
6.Fullerton B, Nolte E, Erler A: Qualität der Versorgung chronisch Kranker in Deutschland. Z Evid Fortbild Qual Gesundhwes. 2011; 105: 554–62. CrossRef MEDLINE
7.Busse R, Blümel M, Ognyanova D: Das deutsche Gesundheitssystem. Akteure, Daten, Analysen Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft 2013.
8.Busse R: Disease management programs in Germany's statutory health insurance system. Health Aff 2004; 23: 56–67. CrossRef MEDLINE
9.Bundesversicherungsamt (BVA): Grundlegende Informationen zu Disease Management Programmen (DMP). www.bundesversicherungsamt.de/weitere-themen/disease-management-programme/zulassung-disease-management-programme-dmp.html#c207 (last accessed on 3 june 2014)
10.Gerlach F, Beyer M, Szecsenyi J, Raspe H: Evaluation von Disease-Management-Programmen – Aktuelle Defizite, Anforderungen, Methoden. Z Arztl Fortbild Qualitatssich 2003; 97: 495–501. MEDLINE
11.Morfeld M, Wirtz M: Methods in health services research. The example of the evaluation of the German disease management programmes. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2006; 49: 120–9. CrossRef MEDLINE
12.Egginton JS, Ridgeway JL, Shah ND, et al.: Care management for Type 2 diabetes in the United States: a systematic review and meta-analysis. BMC Health Serv Res 2012; 12: 72. CrossRef MEDLINE PubMed Central
13.Pimouguet C, Le Goff M, Thiébaut R, Dartiques JF, Helmer C: Effectiveness of disease-management programs for improving diabetes care: a meta-analysis. CMAJ 2011; 183: E115–27. CrossRef MEDLINE PubMed Central
14.De Bruin SR, Heijink R, Lemmens L, Struijs JN, Baan CA: Impact of disease management programs on healthcare expenditures for patients with diabetes, depression, heart failure or chronic obstructive pulmonary disease: a systematic review of the literature. Health Policy 2011; 101: 105–21. CrossRef MEDLINE
15.Mattke S, Seid M, Ma S: Evidence for the effect of disease management: is $1 billion a year a good investment? Am J Manag Care 2007; 13: 670–6. CrossRef
16.Knight K, Badamgarav E, Henning JM, et al.: A systematic review of diabetes disease management programs. Am J Manag Care 2005; 11: 242–50. MEDLINE
17.Ofman JJ, Badamgarav E, Henning JM, et al.: Does disease management improve clinical and economic outcomes in patients with chronic diseases? A systematic review. Am J Med. 2004; 117: 182–92. CrossRef MEDLINE
18.Norris SL, Nichols PJ, Caspersen CJ, et al.: The effectiveness of disease and case management for people with diabetes. A systematic review. Am J Prev Med. 2002; 22(4 Suppl): 15–38. CrossRef MEDLINE
19.Drabik A, Büscher G, Sawicki PT, et al.: Life prolonging of disease management programs in patients with type 2 diabetes is cost-effective. Diabetes Res Clin Pract 2012; 95: 194–200. CrossRef MEDLINE
20.Drabik A, Büscher G, Thomas K, Graf C, Müller D, Stock S: Patients with type 2 diabetes benefit from primary care-based disease management: A propensity score matched survival time analysis. Popul Health Manag 2012; 15: 241–7. CrossRef MEDLINE
21.Drabik A, Graf C, Büscher G, Stock S: Evaluation der Effektivität eines Disease Management Programms Diabetes Mellitus in der GKV – Erste Ergebnisse und methodische Überlegungen. Z Evid Fortbild Qual Gesundhwes 2012; 106: 649–55. CrossRef MEDLINE
22.Stock S, Drabik A, Büscher G et al.: German diabetes management programs improve quality of care and curb costs. Health Aff 2010; 29: 2197–205. CrossRef MEDLINE
23.Ullrich W, Marschall U, Graf C: Versorgungsmerkmal des Diabetes mellitus in Disease-Management-Programmen. Ein Vergleich von in die DMP eingeschriebenen und nicht eingeschriebenen Versicherten mit Diabetes. Diabetes, Stoffwechsel und Herz 2007; 16: 407–14.
24.Elkeles T, Kirschner W, Graf C, Kellermann-Mühlhoff P: Health care in and outside a DMP for type 2 diabetes mellitus in Germany – results of an insurance customer survey focussing on differences in general education status. J Public Health 2009; 17: 205–16. CrossRef
25.Graf C, Elkeles T, Kirschner W: Gibt es einen Selektionsbias im DMP? Z Allg Med 2009; 85: 74–81.
26.Linder R, Ahrens S, Koppel D, Heilmann T, Verheyen F: The benefit and efficiency of the disease management program for type 2 diabetes. Dtsch Arztebl Int 2011; 108: 155–62. VOLLTEXT
27.Nolting HD, Gottberg A, Schiffhorst G, Buhr S, Engel J: Einfluss der Teilnahme am DMP Diabetes mellitus Typ 2 auf die Entwicklung der Leistungsausgaben – Ergebnisse einer retrospektiven kontrollierten Studie auf der Basis von GKV-Routinedaten. Gesundh ökon Qual manag 2011; 16: 209–15. CrossRef
28.Miksch A, Laux G, Ose D, et al.: Is there a survival benefit within a German primary care-based disease management program? Am J Manag Care 2010; 16: 49–54. MEDLINE
29.Miksch A, Hermann K, Trieschmann J, et al.: Geschlechtsspezifische Unterschiede in der Lebensqualität von Typ-2-Diabetikern mit und ohne DMP-Einschreibung. Gesundheitswesen 2008; 70: 250–5. CrossRef MEDLINE
30.Ose D, Freund T, Urban E, Kunz C, Szecsenyi J, Miksch A: Comorbidity and patient-reported quality of care: An evaluation of the primary care based German disease management program for type 2 diabetes. J Public Health 2011; 20: 41–6. CrossRef
31.Ose D, Miksch A, Urban E, et al.: Health related quality of life and comorbidity. A descriptive analysis comparing EQ-5D dimensions of patients in the German disease management program for type 2 diabetes and patients in routine care. BMC Health Serv Res 2011; 11: 179. CrossRef MEDLINE PubMed Central
32.Szecsenyi J, Rosemann T, Joos S, Peters-Klimm F, Miksch A: German diabetes disease management programs are appropriate for restructuring care according to the chronic care model: an evaluation with the patient assessment of chronic illness care instrument. Diabetes Care 2008; 31: 1150–4. CrossRef MEDLINE
33.Schäfer I, Küver C, Gedrose B, et al.: The disease management program for type 2 diabetes in Germany enhances process quality of diabetes care – a follow-up survey of patient's experiences. BMC Health Serv Res 2010; 10: 55. CrossRef MEDLINE PubMed Central
34.Stark R, Schunk M, Meisinger C, Rathmann W, Leidl R, Holle R: Medical care of type 2 diabetes in German disease management programmes: a population-based evaluation. Diabetes Metab Res Rev 2011; 27: 383–91. CrossRef MEDLINE
35.Stark R, Schunk M, Leidl R, Meisinger C, Holle R: Prozeßevaluation von Disease Management Programmen bei Typ 2 Diabetes auf Basis einer bevölkerungsrepräsentativen Studie in der Region Augsburg (KORA). BFuP 2009; 61: 283–301.
36.Drabik A, Sawicki PT, Müller D, Passon A, Stock S: Die Methoden der Evaluation von Disease Management Programmen im Kontrollgruppendesign am Beispiel Diabetes mellitus – Eine systematische Übersicht. Gesundheitswesen 2012; 74: 496–501. CrossRef MEDLINE
37.Conklin A, Hinrichs S: DISMEVAL Developing and validating disease management evaluation methods for European healthcare systems. Final report. Cambridge: RAND Corporation 2012.
38.Conklin A, Nolte E: Disease management evaluation: A comprehensive review of current state of the art. Cambridge: RAND Corporation 2011.